Medpace Holdings Inc (NASDAQ:MEDP) major shareholder Medpace Investors, Llc sold 214,499 shares of Medpace stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $127.23, for a total transaction of $27,290,707.77. Following the completion of the sale, the insider now owns 7,542,057 shares in the company, valued at $959,575,912.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Medpace Investors, Llc also recently made the following trade(s):

  • On Thursday, July 30th, Medpace Investors, Llc sold 42,955 shares of Medpace stock. The shares were sold at an average price of $120.79, for a total transaction of $5,188,534.45.
  • On Friday, July 24th, Medpace Investors, Llc sold 34,380 shares of Medpace stock. The shares were sold at an average price of $106.13, for a total transaction of $3,648,749.40.
  • On Wednesday, July 22nd, Medpace Investors, Llc sold 63,968 shares of Medpace stock. The shares were sold at an average price of $108.58, for a total transaction of $6,945,645.44.
  • On Monday, July 20th, Medpace Investors, Llc sold 37,044 shares of Medpace stock. The shares were sold at an average price of $105.39, for a total transaction of $3,904,067.16.
  • On Thursday, July 16th, Medpace Investors, Llc sold 15,273 shares of Medpace stock. The shares were sold at an average price of $103.70, for a total transaction of $1,583,810.10.
  • On Monday, July 13th, Medpace Investors, Llc sold 6,127 shares of Medpace stock. The shares were sold at an average price of $100.50, for a total transaction of $615,763.50.
  • On Thursday, July 9th, Medpace Investors, Llc sold 2,455 shares of Medpace stock. The shares were sold at an average price of $100.15, for a total transaction of $245,868.25.

Shares of NASDAQ:MEDP opened at $119.35 on Friday. The company has a quick ratio of 0.89, a current ratio of 0.94 and a debt-to-equity ratio of 0.16. Medpace Holdings Inc has a twelve month low of $58.72 and a twelve month high of $144.49. The stock’s 50 day moving average is $96.91 and its 200-day moving average is $88.75. The firm has a market capitalization of $4.23 billion, a price-to-earnings ratio of 42.47 and a beta of 1.22.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, July 27th. The company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.40 by $0.28. Medpace had a return on equity of 16.05% and a net margin of 12.11%. The company had revenue of $205.00 million for the quarter, compared to analyst estimates of $181.17 million. During the same period in the prior year, the firm earned $0.81 earnings per share. Medpace’s revenue for the quarter was down 4.3% on a year-over-year basis. Equities research analysts anticipate that Medpace Holdings Inc will post 2.36 earnings per share for the current fiscal year.

A number of equities research analysts have recently weighed in on the company. Wolfe Research downgraded Medpace from an “outperform” rating to a “peer perform” rating and set a $91.00 target price for the company. in a report on Wednesday, May 13th. Robert W. Baird raised Medpace from an “underperform” rating to a “neutral” rating and set a $83.00 target price for the company in a research note on Monday, June 8th. Zacks Investment Research upgraded Medpace from a “hold” rating to a “strong-buy” rating and set a $137.00 price target on the stock in a report on Saturday. Credit Suisse Group boosted their price target on Medpace from $92.00 to $114.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, SunTrust Banks upped their target price on Medpace from $95.00 to $124.00 and gave the company a “hold” rating in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $103.29.

Several large investors have recently modified their holdings of the company. Guggenheim Capital LLC raised its position in shares of Medpace by 3.1% during the fourth quarter. Guggenheim Capital LLC now owns 4,268 shares of the company’s stock worth $359,000 after purchasing an additional 128 shares during the period. Oregon Public Employees Retirement Fund raised its position in Medpace by 1.4% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 11,032 shares of the company’s stock valued at $1,026,000 after buying an additional 150 shares during the last quarter. Sheets Smith Wealth Management raised its position in Medpace by 4.7% in the 1st quarter. Sheets Smith Wealth Management now owns 3,707 shares of the company’s stock valued at $272,000 after buying an additional 167 shares during the last quarter. Optimum Investment Advisors raised its position in Medpace by 3.3% in the 1st quarter. Optimum Investment Advisors now owns 6,200 shares of the company’s stock valued at $455,000 after buying an additional 200 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its position in Medpace by 12.1% in the 1st quarter. Nisa Investment Advisors LLC now owns 2,185 shares of the company’s stock valued at $160,000 after buying an additional 235 shares during the last quarter. 79.83% of the stock is currently owned by institutional investors.

Medpace Company Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

See Also: How do taxes affect a CDs total return?

Insider Buying and Selling by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.